References
- South Africa HIV and AIDS statistics. AVERT [homepage on the Internet]. c2012. Available from: http://www.avert.org/south-africa-hiv-aids-statistics.htm
- Geddes R, Knight S, Moosa M, et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J. 2006; 96(8): 722–724.
- Osler M, Stead D, Rebe K, et al. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med. 2010; 11(2): 121–129.
- Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis. 2007; 45(2): 254–260.
- Falca V, Crespo M, Ribera E. Lactic acidosis related to nucleoside therapy in HIV-infected patients. Expert Opin Pharmacother. 2003; 4(8): 1321–1329.
- Arenas-Pinto A, Grant A, Edwards S, Weller IV. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect. 2003; 79(4): 340–343.
- Walker UA. Lactic acidosis in HIV-patients: diagnosis and treatment. MMW Fortschr Med. 2004; 146 Spec No 1: 65–67.
- Birkus G, Hitchcock JMH, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002, 46(3): 716–713.
- Sánchez-Conde M, de Mendoza C, Jiménez-Nacher I, et al. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials. 2005; 6(4): 197–202.
- Matthews L, Giddy J, Ghebremichael M, et al. A risk factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy PLoS One. 2011; 6(4): e18736.
- Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001; 33(11): 1931–1937.
- Faeh D, Braun J, Bopp M. Prevalence of obesity in Switzerland 1992–2007: the impact of education, income and occupational class. Obes Rev. 2011; 12(3): 151–166.
- Joubert J, Norman R, Bradshaw D, et al. Estimating the burden of disease attributable to excess body weight in South Africa in 2000. S Afr Med J. 2007; 97(8 Pt 2): 683–690.
- Bonnet F, Balestre E, Bernardin E, et al. Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999–2003. Antivir Chem Chemother 2005; 16(1): 63–67.
- Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother. 2007; 8(5): 679–688.